Table 1.
Patient characteristics
| Characteristic | Value or no. of patients (%) | ||
|---|---|---|---|
| No LS (n = 75) | With LSa (n = 31) | ||
| Age, years | |||
| Median (range) | 37 (19–73) | 32.0 (18–61) | |
| Sex | |||
| Female | 40 (53) | 21 (68) | |
| Male | 35 (47) | 10 (32) | |
| Ethnicity | |||
| Caucasian | 59 (78.6) | 25 (81) | |
| African-American | 4 (5.4) | 2 (6) | |
| Hispanic | 10 (13.4) | 4 (12) | |
| Mid-eastern | 2 (2.6) | 0 | |
| Histology | |||
| Hodgkin lymphoma | 56 (75) | 26 (84) | |
| Non-Hodgkin lymphoma | 19 (25) | 5 (16) | |
| Disease stage | |||
| I | 3 (4) | 3 (10) | |
| II | 55 (73.5) | 24 (77) | |
| III | 2 (3) | 2 (6.5) | |
| IV | 4 (5) | 2 (6.5) | |
| Recurrent | 3 (4) | ||
| Refractory | 6 (8) | ||
| Unknown | 2 (3) | ||
| Radiation technique | |||
| IMRT | 71 (95) | 29 (94) | |
| IMRT & 3D AP/PA | 3 (4) | 1 (3) | |
| Protons | 1 (1) | 1 (3) | |
| RT dose, Gy | |||
| Mean (range) | 32.9 (20–46) | 33.2 (30.6–46.6) | |
| ≤30.6 | 49 (65) | 22 (71) | |
| >30.6 | 26 (35) | 9 (29) | |
| 30–36 | 10 (13) | 2 (6.5) | |
| 36–45 | 16 (22) | 7 (22.5) | |
| Peripheral neuropathyb | |||
| Yes | 35 (47) | 16 (52) | |
| No | 39 (52) | 14 (45) | |
| Unknown | 1 (1) | 1 (3) | |
| Bleomycin toxicityb | |||
| Yes | 62 (83) | 7 (23) | |
| No | 3 (4) | 24 (77) | |
| Decreased lung functionc | |||
| Yes | 10 (13) | 11 (35) | |
| No | 65 (87) | 20 (65) | |
Abbreviations: IMRT, intensity-modulated radiation therapy; 3D AP/PA, three-dimensional conformal radiation therapy with anteroposterior/posteroanterior fields
aLS at some time during follow-up
bAfter chemotherapy but before radiation therapy
cOut of the 106 patients pulmonary function tests were performed in only 43 patients